Mizuki Kaneshiro

Yamato, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.

Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension

Published: November 30, 2022

Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake.

Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake.

Journal: Journal of diabetes investigation

Published: October 14, 2022

A cross-sectional study of the relationship between quality of life and sleep quality in Japanese patients with type 1 diabetes mellitus.

A cross-sectional study of the relationship between quality of life and sleep quality in Japanese patients with type 1 diabetes mellitus.

Journal: Endocrine journal

Published: December 02, 2021

Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study.

Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: September 02, 2021

Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.

Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: June 17, 2021

Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.

Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.

Journal: Diabetes technology & therapeutics

Published: February 05, 2020

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.

Journal: Journal of diabetes investigation

Published: December 06, 2019

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.

Journal: Journal of clinical medicine research

Published: November 02, 2018

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.

Journal: Journal of clinical medicine research

Published: May 07, 2018

Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study.

Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study.

Journal: Journal of diabetes investigation

Published: March 19, 2018

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

Journal: Journal of clinical medicine research

Published: May 25, 2017

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

Journal: Journal of clinical medicine research

Published: April 11, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026